Cancer Prevention Pharmaceuticals, Inc.

Release Summary

Data Monitoring Committee recommends continuation of Cancer Prevention Pharmaceuticals' Phase 3 trial in rare disease, familial adenomatouspolyposis.

Cancer Prevention Pharmaceuticals, Inc.